65jaoya,

You bring up a very very interesting topic. Now that the BETonMACE database is locked, all those thousands of patient years of unblinded data are being closely looked at. There is keen interest in ensuring that the test drug, apabetalone, does not present any safety concerns and increase risk of adverse events. An extremely encouraging statement from the top-line news release is that "Apabetalone demonstrated tolerability and safety." What might not be appreciated right now is that there is also going to be ample patient data to determine if apabetalone actually decreased the incidence of any unexpected/unanticipated health/disease outcomes. Resverlogix and the clinical team may have pre-specified a lot of things to look at. However, there could be some very promising surprises, such as decreased cancer incidence, elicited by apabetalone in BETonMACE. The full data reveal at AHA (and hopefully the simultaneous publication in a medical journal) will have these details. Tick tock!

BDAZ